Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global PD-1 Inhibitor Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by PD-1 Inhibitor Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global PD-1 Inhibitor Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Pembrolizumab
    • 1.4.3 Nivolumab
    • 1.4.4 Atezolizumab
    • 1.4.5 Durvalumab
    • 1.4.6 Avelumab
    • 1.4.7 Other
  • 1.5 Market by Application
    • 1.5.1 Global PD-1 Inhibitor Market Share by Application: 2020 VS 2026
    • 1.5.2 Melanoma
    • 1.5.3 Non-small Cell Lung Cancer (NSCLC)
    • 1.5.4 Urothelial Carcinoma
    • 1.5.5 Classical Hodgkin Lymphoma
    • 1.5.6 Renal Cell Carcinoma
    • 1.5.7 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): PD-1 Inhibitor Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the PD-1 Inhibitor Industry
      • 1.6.1.1 PD-1 Inhibitor Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and PD-1 Inhibitor Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for PD-1 Inhibitor Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 PD-1 Inhibitor Market Perspective (2015-2026)
  • 2.2 PD-1 Inhibitor Growth Trends by Regions
    • 2.2.1 PD-1 Inhibitor Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 PD-1 Inhibitor Historic Market Share by Regions (2015-2020)
    • 2.2.3 PD-1 Inhibitor Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 PD-1 Inhibitor Market Growth Strategy
    • 2.3.6 Primary Interviews with Key PD-1 Inhibitor Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top PD-1 Inhibitor Players by Market Size
    • 3.1.1 Global Top PD-1 Inhibitor Players by Revenue (2015-2020)
    • 3.1.2 Global PD-1 Inhibitor Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global PD-1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global PD-1 Inhibitor Market Concentration Ratio
    • 3.2.1 Global PD-1 Inhibitor Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by PD-1 Inhibitor Revenue in 2019
  • 3.3 PD-1 Inhibitor Key Players Head office and Area Served
  • 3.4 Key Players PD-1 Inhibitor Product Solution and Service
  • 3.5 Date of Enter into PD-1 Inhibitor Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global PD-1 Inhibitor Historic Market Size by Type (2015-2020)
  • 4.2 Global PD-1 Inhibitor Forecasted Market Size by Type (2021-2026)

5 PD-1 Inhibitor Breakdown Data by Application (2015-2026)

  • 5.1 Global PD-1 Inhibitor Market Size by Application (2015-2020)
  • 5.2 Global PD-1 Inhibitor Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America PD-1 Inhibitor Market Size (2015-2020)
  • 6.2 PD-1 Inhibitor Key Players in North America (2019-2020)
  • 6.3 North America PD-1 Inhibitor Market Size by Type (2015-2020)
  • 6.4 North America PD-1 Inhibitor Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe PD-1 Inhibitor Market Size (2015-2020)
  • 7.2 PD-1 Inhibitor Key Players in Europe (2019-2020)
  • 7.3 Europe PD-1 Inhibitor Market Size by Type (2015-2020)
  • 7.4 Europe PD-1 Inhibitor Market Size by Application (2015-2020)

8 China

  • 8.1 China PD-1 Inhibitor Market Size (2015-2020)
  • 8.2 PD-1 Inhibitor Key Players in China (2019-2020)
  • 8.3 China PD-1 Inhibitor Market Size by Type (2015-2020)
  • 8.4 China PD-1 Inhibitor Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan PD-1 Inhibitor Market Size (2015-2020)
  • 9.2 PD-1 Inhibitor Key Players in Japan (2019-2020)
  • 9.3 Japan PD-1 Inhibitor Market Size by Type (2015-2020)
  • 9.4 Japan PD-1 Inhibitor Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia PD-1 Inhibitor Market Size (2015-2020)
  • 10.2 PD-1 Inhibitor Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia PD-1 Inhibitor Market Size by Type (2015-2020)
  • 10.4 Southeast Asia PD-1 Inhibitor Market Size by Application (2015-2020)

11 India

  • 11.1 India PD-1 Inhibitor Market Size (2015-2020)
  • 11.2 PD-1 Inhibitor Key Players in India (2019-2020)
  • 11.3 India PD-1 Inhibitor Market Size by Type (2015-2020)
  • 11.4 India PD-1 Inhibitor Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America PD-1 Inhibitor Market Size (2015-2020)
  • 12.2 PD-1 Inhibitor Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America PD-1 Inhibitor Market Size by Type (2015-2020)
  • 12.4 Central & South America PD-1 Inhibitor Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Merck
    • 13.1.1 Merck Company Details
    • 13.1.2 Merck Business Overview and Its Total Revenue
    • 13.1.3 Merck PD-1 Inhibitor Introduction
    • 13.1.4 Merck Revenue in PD-1 Inhibitor Business (2015-2020))
    • 13.1.5 Merck Recent Development
  • 13.2 Novartis
    • 13.2.1 Novartis Company Details
    • 13.2.2 Novartis Business Overview and Its Total Revenue
    • 13.2.3 Novartis PD-1 Inhibitor Introduction
    • 13.2.4 Novartis Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.2.5 Novartis Recent Development
  • 13.3 Onxeo
    • 13.3.1 Onxeo Company Details
    • 13.3.2 Onxeo Business Overview and Its Total Revenue
    • 13.3.3 Onxeo PD-1 Inhibitor Introduction
    • 13.3.4 Onxeo Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.3.5 Onxeo Recent Development
  • 13.4 Sumitomo Dainippon Pharma
    • 13.4.1 Sumitomo Dainippon Pharma Company Details
    • 13.4.2 Sumitomo Dainippon Pharma Business Overview and Its Total Revenue
    • 13.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Introduction
    • 13.4.4 Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.4.5 Sumitomo Dainippon Pharma Recent Development
  • 13.5 Taiwan Liposome Company
    • 13.5.1 Taiwan Liposome Company Company Details
    • 13.5.2 Taiwan Liposome Company Business Overview and Its Total Revenue
    • 13.5.3 Taiwan Liposome Company PD-1 Inhibitor Introduction
    • 13.5.4 Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.5.5 Taiwan Liposome Company Recent Development
  • 13.6 Tiziana Life Sciences
    • 13.6.1 Tiziana Life Sciences Company Details
    • 13.6.2 Tiziana Life Sciences Business Overview and Its Total Revenue
    • 13.6.3 Tiziana Life Sciences PD-1 Inhibitor Introduction
    • 13.6.4 Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.6.5 Tiziana Life Sciences Recent Development
  • 13.7 Genentech (Roche)
    • 13.7.1 Genentech (Roche) Company Details
    • 13.7.2 Genentech (Roche) Business Overview and Its Total Revenue
    • 13.7.3 Genentech (Roche) PD-1 Inhibitor Introduction
    • 13.7.4 Genentech (Roche) Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.7.5 Genentech (Roche) Recent Development
  • 13.8 AstraZeneca
    • 13.8.1 AstraZeneca Company Details
    • 13.8.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.8.3 AstraZeneca PD-1 Inhibitor Introduction
    • 13.8.4 AstraZeneca Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.8.5 AstraZeneca Recent Development
  • 13.9 Pfizer
    • 13.9.1 Pfizer Company Details
    • 13.9.2 Pfizer Business Overview and Its Total Revenue
    • 13.9.3 Pfizer PD-1 Inhibitor Introduction
    • 13.9.4 Pfizer Revenue in PD-1 Inhibitor Business (2015-2020)
    • 13.9.5 Pfizer Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global PD-1 Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PD-1 Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Merck
    Novartis
    Onxeo
    Sumitomo Dainippon Pharma
    Taiwan Liposome Company
    Tiziana Life Sciences
    Genentech (Roche)
    AstraZeneca
    Pfizer

    Market segment by Type, the product can be split into
    Pembrolizumab
    Nivolumab
    Atezolizumab
    Durvalumab
    Avelumab
    Other
    Market segment by Application, split into
    Melanoma
    Non-small Cell Lung Cancer (NSCLC)
    Urothelial Carcinoma
    Classical Hodgkin Lymphoma
    Renal Cell Carcinoma
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global PD-1 Inhibitor status, future forecast, growth opportunity, key market and key players.
    To present the PD-1 Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of PD-1 Inhibitor are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now